These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 10696744

  • 1. Histopathologic changes in retinoblastoma after chemoreduction.
    Dithmar S, Aabert TM, Grossniklaus HE.
    Retina; 2000; 20(1):33-6. PubMed ID: 10696744
    [Abstract] [Full Text] [Related]

  • 2. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction.
    Demirci H, Eagle RC, Shields CL, Shields JA.
    Arch Ophthalmol; 2003 Aug; 121(8):1125-31. PubMed ID: 12912690
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation.
    Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, Friedman DL, Naduvilath TJ.
    Am J Ophthalmol; 2002 May; 133(5):657-64. PubMed ID: 11992863
    [Abstract] [Full Text] [Related]

  • 5. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma.
    Shields CL, Shields JA, Needle M, de Potter P, Kheterpal S, Hamada A, Meadows AT.
    Ophthalmology; 1997 Dec; 104(12):2101-11. PubMed ID: 9400771
    [Abstract] [Full Text] [Related]

  • 6. Treatment of intraocular retinoblastoma with vincristine and carboplatin.
    Rodriguez-Galindo C, Wilson MW, Haik BG, Merchant TE, Billups CA, Shah N, Cain A, Langston J, Lipson M, Kun LE, Pratt CB.
    J Clin Oncol; 2003 May 15; 21(10):2019-25. PubMed ID: 12743157
    [Abstract] [Full Text] [Related]

  • 7. Chemoreduction for unilateral retinoblastoma.
    Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Naduvilath TJ.
    Arch Ophthalmol; 2002 Dec 15; 120(12):1653-8. PubMed ID: 12470138
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinicopathologic features of retinoblastoma after primary chemoreduction.
    Bechrakis NE, Bornfeld N, Schueler A, Coupland SE, Henze G, Foerster MH.
    Arch Ophthalmol; 1998 Jul 15; 116(7):887-93. PubMed ID: 9682701
    [Abstract] [Full Text] [Related]

  • 11. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, Shields JA.
    Arch Ophthalmol; 2005 Jun 15; 123(6):765-73. PubMed ID: 15955977
    [Abstract] [Full Text] [Related]

  • 12. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients.
    Shields CL, Shelil A, Cater J, Meadows AT, Shields JA.
    Arch Ophthalmol; 2003 Nov 15; 121(11):1571-6. PubMed ID: 14609913
    [Abstract] [Full Text] [Related]

  • 13. Retinoma underlying retinoblastoma revealed after tumor response to 1 cycle of chemotherapy.
    Dimaras H, Khetan V, Halliday W, Héon E, Chan HS, Gallie BL.
    Arch Ophthalmol; 2009 Aug 15; 127(8):1066-8. PubMed ID: 19667353
    [No Abstract] [Full Text] [Related]

  • 14. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.
    Shields CL, Ramasubramanian A, Thangappan A, Hartzell K, Leahey A, Meadows AT, Shields JA.
    Ophthalmology; 2009 Mar 15; 116(3):544-551.e1. PubMed ID: 19157557
    [Abstract] [Full Text] [Related]

  • 15. Residual intraretinal retinoblastoma after chemoreduction failure.
    Hwang CK, Aaberg TM, Chevez-Barrios P, Verner-Cole E, Gombos DS, Paysse E, Chintagumpala M, Gao W, Grossniklaus HE.
    Arch Ophthalmol; 2012 Feb 15; 130(2):246-8. PubMed ID: 22332223
    [No Abstract] [Full Text] [Related]

  • 16. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma.
    Shields CL, Honavar SG, Shields JA, Demirci H, Meadows AT, Naduvilath TJ.
    Arch Ophthalmol; 2002 Apr 15; 120(4):460-4. PubMed ID: 11934319
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.
    Shields CL, Mashayekhi A, Cater J, Shelil A, Meadows AT, Shields JA.
    Trans Am Ophthalmol Soc; 2004 Apr 15; 102():35-44; discussion 44-5. PubMed ID: 15747743
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.